Central subfield thickness (CST) after the loading phase is a strong predictor of injection frequency and recurrence timing in patients with neovascular age-related macular degeneration (nAMD) undergoing a treat-and-extend (T&E) regimen, according to a study. Monitoring early treatment response with optical coherence tomography (OCT) can help personalize anti-VEGF therapy, optimizing treatment intervals while minimizing overtreatment.
Researchers conducted a retrospective analysis of treatment-naïve patients receiving intravitreal aflibercept under a treat-and-extend (T&E) regimen.
Following 3 initial monthly loading doses, patients underwent modified T&E treatment, with OCT parameters and best-corrected visual acuity (BCVA) monitored. Post-loading central subfield thickness (CST) was a significant predictor of injection frequency and recurrence timing, while baseline CST and BCVA showed no correlation. BCVA remained stable across groups with different treatment needs, and type 2 macular neovascularization demonstrated a faster response compared to type 1.
Reference
Lim G, Kim KT, Kim DY, et al. Early optical coherence tomography biomarkers for tailored frequency of intravitreal aflibercept in neovascular age-related macular degeneration. Sci Rep. 2025;15(1):8911. doi: 10.1038/s41598-025-93962-x. PMID: 40087500.
Related Content
